drugset / Trial / NCT00082576

Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of Uncomplicated Malaria in Africa

NCT00082576

Phase 2/3 Completed 238 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective is to confirm the hypothesis that azithromycin plus chloroquine is non-inferior to mefloquine for the treatment of symptomatic, uncomplicated malaria due to P. falciparum.

Timeline

Start
2004-06
Primary completion
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 500 mg
Subject Azithromycin Small molecule 1000 mg
Subject Chloroquine Small molecule 600 mg
Subject Mefloquine Unknown 1250 mg